Home | Substack

It Works Too Well. Early research suggests that psilocybin therapy can cause remission of depressive symptoms in one to three sessions. Contrast that with SSRIs like Prozac, which patients take (and insurance companies pay for) for the rest of their lives. That means that there’s little recurring revenue, so COMPASS needs to convince the payers to ... See more

The Psychedelic Ecosystem will have the best chance of ensuring access, establishing robust businesses, and mitigating existential risk by eschewing legalized consumer models and promoting psychedelics as medicine and enacting decriminalization measures.

The big picture: While research continues, psychedelic medicine could reshape the future of healthcare and wellness. As momentum builds, scientists, startups, investors, and big pharma are plotting their next move.

Because of long-held negative or recreational associations, most people are unaware that psychedelics are the most promising treatment for a wide range of mental health issues -- from depression to alcoholism to anorexia -- that we’ve ever seen.

It is known that the likelihood of long-term therapeutic gains increases with the likelihood of the subject having a mystical experience, prima facie evidence favoring a critical role for subjectivity. It is precisely the high emotional impact of the memories of the vivid and highly unusual psychedelic experience that serves as the primary source o

... See more